Jean Poulos, M.S, M.B.A., new Principal Consultant at Lachman Consultant Services, Inc.

We are pleased to announce that Jean Poulos has accepted the position of Principal Consultant in the Regulatory Practice at Lachman Consultants, effective April 10, 2017.

Ms. Poulos is a seasoned Regulatory professional with more than 25 years of combined quality assurance, quality control, regulatory affairs and compliance enforcement experience in the pharmaceutical / biotechnology industries.  She is a former FDA Investigator with extensive industry experience.  She is highly knowledgeable in U.S. FDA regulatory filing requirements, technical applications, and Quality Systems.

Prior to joining Lachman, Ms. Poulos served as Vice President, Quality and Compliance and Regulatory at Rising Pharmaceuticals, was Vice President, Global Regulatory at Aceto, served as Senior Director, Regulatory Intelligence and Outreach at Johnson and Johnson, and was Vice President, Quality and Regulatory Operations at Luitpold Pharmaceuticals.  She began her career as an Investigator at the Food and Drug Administration before joining the industry in various Regulatory roles.

Ms. Poulos was awarded an M.S. in Industrial Pharmacy from St. John’s University of New York, an M.B.A. from Long Island University, C.W. Post, and a B.A. in Biology from Queens College, CUNY.

We welcome Jean to her new role of Principal Consultant and wish her a long and successful career with Lachman Consultants.

For nearly four decades, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available.  Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutions based on the integration of scientific principles, evolving regulatory expectations, and technology.